Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer

 Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer

Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer

Shots:

  • Aurigene to receive 10M upfront while Exelixis get an option to license three developed programs from Aurigene. Additionally, Exelixis and Aurgene is developing three discovery programs, for which Exelixis will pay $2.5M/program in exchange for exclusive rights for the program
  • Exelixis will provide R&D funding for all programs. Exelixis can exercise its option until IND acceptance, if exercised, it will pay option exercise fee along with milestones payment and royalties. Aurigene will retain development & commercialization rights of the program in India & Russia
  • The focus of the agreement is to expand Exelixis’s oncology portfolio apart from its lead candidate, Cabometyx (cabozantinib) which is indicated for the treatment of advanced renal cell carcinoma in patients prior treated with anti-angiogenic therapy

Click here to­ read full press release/ article | Ref: Business Wire | Image: Bio Spectrum

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post